Nusinersen
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Nusinersen
Nusinersen: Known uses and market status in Canada
Summary
The TxGNN deep-learning model produced no candidate with a score of 0.99 or higher for Nusinersen, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 2 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| spinal muscular atrophy | licence in another country |
| spinraza is indicated for the treatment of 5q spinal muscular atrophy | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02465663 | SPINRAZA | Valid |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report, and no drug interaction records were found. Please refer to the package insert for safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.